Document is current

Article History

Received: 7 July 2025

Accepted: 22 November 2025

First Online: 4 February 2026

Declarations

:

: The study was approved by the Justus-Liebig University ethics committee (189/22 and 53/23).

: All patients gave informed consent.

: Potential conflicts of interest are related to the manufacturers of the endplate-protecting treatments discussed here: UCB (zilocuplan), Argenx (efgartigimod alfa), Alexion (ravulizumab). SG declares travel reimbursements from Alexion. SP declares travel reimbursements and consulting fees from Alexion. HHK declares lecturing honoraria and consulting fees from Alexion, Argenx, and UCB, travel reimbursements of Alexion, and research support from Roche and Argenx. AM, JE and CB declare no conflicts of interest.AM: declares no conflicts of interestSG: declares no conflicts of interest.JE: declares no conflicts of interestCB: received honoraria for lecturing and for serving on advisory boards from Bayer, Novartis, and Portola.SP: received honoraria for lecturing and for serving on advisory boards from Argenx, Alexion, Biogen, Hexal, Merck Healthcare, Novartis, Roche, and Sanofi Aventis; travel reimbursements from Alexion, Biogen, Merck Healthcare, neuraxpharm, and Roche; research support from Biogen, Merck Healthcare, and Novartis.HHK: received honoraria for lecturing and for serving on advisory boards from Alexion, Alnylam, Amgen, Argenx, Roche, Sanofi Aventis, and UCB; travel reimbursements from Alexion, Alnylam, Griffols, and Sanofi Aventis; research support from Argenx and Roche.